Literature DB >> 19330428

Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.

YuXiang Wei1, DeHua Zheng, Li Xiao, BingYi Shi.   

Abstract

BACKGROUND: Prothrombin time is widely utilized for evaluation of liver disease severity. However, its standardization of modes of reporting is not established for universal purpose. Variability in thromboplastin reagents leads to large intralaboratory and interlaboratory differences in PT results.
OBJECTIVE: The aim of this study was to establish standardization of modes of PT reporting by the interchangeability analysis of prothrombin time in patients with advanced liver disease associated with viral hepatitis measured with different thromboplastin reagents by the use of various methods of expression, i.e. prothrombin time (PTs), prothrombin activity percentage (PTp), prothrombin time ratio (PTr) and International Normalized Ratio (INR).
METHODS: we prospectively collected blood samples from 61 patients with advanced liver disease associated with viral hepatitis, control patients were on warfarin (n = 20). PT was measured on a STA-R with six thromboplastin reagents. PT was expressed in PTs, PTr, PTp, and INR. Neoplastin was selected as reference reagent for comparison of methods of reporting.
RESULTS: The study revealed the closest agreement of the results in study population between Neoplastin and the other five reagents, and the regression lines of these reagents were close to each other, when the results were expressed in PTp while INR, PTs and PTr is not valid for comparison of patients with liver disease. In patients on oral anticoagulant therapy, only INR standardize PT results.
CONCLUSION: we conclude that, in patients with liver disease, only activity percentage expression may provide a common international scale of PT reporting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330428     DOI: 10.1007/s11239-009-0330-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Prothrombin time in fulminant hepatic failure.

Authors:  S J Munoz
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

Review 2.  Review article: coagulation disorders in chronic liver disease.

Authors:  M Peck-Radosavljevic
Journal:  Aliment Pharmacol Ther       Date:  2007-11       Impact factor: 8.171

Review 3.  Molecular basis of vitamin K-dependent gamma-carboxylation.

Authors:  B Furie; B C Furie
Journal:  Blood       Date:  1990-05-01       Impact factor: 22.113

4.  Recommended method for reporting therapeutic control of oral anticoagulant therapy. Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  A M van den Besselaar
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

5.  Validity of the INR system for patients with liver impairment.

Authors:  K W Denson; S V Reed; M E Haddon
Journal:  Thromb Haemost       Date:  1995-01       Impact factor: 5.249

6.  International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control.

Authors: 
Journal:  Thromb Haemost       Date:  1985-02-18       Impact factor: 5.249

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.

Authors:  R L Carithers; H F Herlong; A M Diehl; E W Shaw; B Combes; H J Fallon; W C Maddrey
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

9.  International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure.

Authors:  Russ Arjal; James F Trotter
Journal:  Clin Liver Dis       Date:  2009-02       Impact factor: 6.126

10.  Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis.

Authors:  J W Fang; G L Bird; T Nakamura; G L Davis; J Y Lau
Journal:  Lancet       Date:  1994-04-02       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.